Literature DB >> 29285498

Non-vitamin K antagonist oral anticoagulant dosing in patients with atrial fibrillation and renal dysfunction.

Ahsan A Khan1, Gregory Y H Lip1,2.   

Abstract

Entities:  

Year:  2017        PMID： 29285498      PMCID： PMC5733324          DOI： 10.21037/atm.2017.09.19

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  20 in total

1.  Guideline-Adherent Antithrombotic Treatment Improves Outcomes in Patients With Atrial Fibrillation: Insights From the Community-Based Darlington Atrial Fibrillation Registry.

Authors:  Michał Mazurek; Eduard Shantsila; Deirdre A Lane; Andreas Wolff; Marco Proietti; Gregory Y H Lip
Journal:  Mayo Clin Proc       Date:  2017-08       Impact factor: 7.616

2.  Postapproval Observational Studies of Non-Vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation.

Authors:  Tatjana S Potpara; Gregory Y H Lip
Journal:  JAMA       Date:  2017-03-21       Impact factor: 56.272

3.  Off-Label Dosing of Non-Vitamin K Antagonist Oral Anticoagulants and Adverse Outcomes: The ORBIT-AF II Registry.

Authors:  Benjamin A Steinberg; Peter Shrader; Laine Thomas; Jack Ansell; Gregg C Fonarow; Bernard J Gersh; Peter R Kowey; Kenneth W Mahaffey; Gerald Naccarelli; James Reiffel; Daniel E Singer; Eric D Peterson; Jonathan P Piccini
Journal:  J Am Coll Cardiol       Date:  2016-12-20       Impact factor: 24.094

4.  "Unreal world" or "real world" data in oral anticoagulant treatment of atrial fibrillation.

Authors:  Ben Freedman; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2016-09-01       Impact factor: 5.249

Review 5.  Atrial fibrillation.

Authors:  Gregory Y H Lip; Laurent Fauchier; Saul B Freedman; Isabelle Van Gelder; Andrea Natale; Carola Gianni; Stanley Nattel; Tatjana Potpara; Michiel Rienstra; Hung-Fat Tse; Deirdre A Lane
Journal:  Nat Rev Dis Primers       Date:  2016-03-31       Impact factor: 52.329

6.  Efficacy and safety of edoxaban in comparison with dabigatran, rivaroxaban and apixaban for stroke prevention in atrial fibrillation. An indirect comparison analysis.

Authors:  Flemming Skjøth; Torben Bjerregaard Larsen; Lars Hvilsted Rasmussen; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2014-02-28       Impact factor: 5.249

7.  Bivariate evaluation of thromboembolism and bleeding in clinical trials of anticoagulants in patients with atrial fibrillation.

Authors:  John M Kittelson; Philippe Gabriel Steg; Jonathan L Halperin; Neil A Goldenberg; Sam Schulman; Alex C Spyropoulos; Craig M Kessler; Alexander G G Turpie; Neal R Cutler; William R Hiatt
Journal:  Thromb Haemost       Date:  2016-06-23       Impact factor: 5.249

8.  Multiple risk factors and ischaemic stroke in the elderly Asian population with and without atrial fibrillation. An analysis of 425,600 Chinese individuals without prior stroke.

Authors:  Yutao Guo; Hao Wang; Yingchun Tian; Yutang Wang; Gregory Y H Lip
Journal:  Thromb Haemost       Date:  2015-08-31       Impact factor: 5.249

9.  Prognosis and treatment of atrial fibrillation patients by European cardiologists: one year follow-up of the EURObservational Research Programme-Atrial Fibrillation General Registry Pilot Phase (EORP-AF Pilot registry).

Authors:  Gregory Y H Lip; Cécile Laroche; Popescu Mircea Ioachim; Lars Hvilsted Rasmussen; Laura Vitali-Serdoz; Lucian Petrescu; Dan Darabantiu; Harry J G M Crijns; Paulus Kirchhof; Panos Vardas; Luigi Tavazzi; Aldo P Maggioni; Giuseppe Boriani
Journal:  Eur Heart J       Date:  2014-08-31       Impact factor: 29.983

10.  Therapy persistence in newly diagnosed non-valvular atrial fibrillation treated with warfarin or NOAC. A cohort study.

Authors:  Carlos Martinez; Anja Katholing; Christopher Wallenhorst; Saul Benedict Freedman
Journal:  Thromb Haemost       Date:  2015-08-06       Impact factor: 5.249
View more
  1 in total

1.  Direct versus conventional anticoagulants for treatment of cancer associated thrombosis: a pooled and interaction analysis between observational studies and randomized clinical trials.

Authors:  Zhi-Chun Gu; Yi-Dan Yan; Sheng-Yan Yang; Long Shen; Ling-Cong Kong; Chi Zhang; An-Hua Wei; Zheng Li; Xin-Hua Wang; Hou-Wen Lin
Journal:  Ann Transl Med       Date:  2020-02
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.